Imunon (NASDAQ: IMNN) director gets 5,892-share option grant on Jan. 2

Rhea-AI Filing Summary

Imunon, Inc. reported that director Frederick J. Fritz received a stock option grant on January 2, 2026. The Form 4 shows a derivative award of a Stock Option (Right to Buy) covering 5,892 shares of Imunon common stock at an exercise price of $3.95 per share, which was the closing stock price on the grant date.

The option was granted for no cash payment and is held directly by Fritz, with 5,892 derivative securities beneficially owned after the transaction. According to the vesting terms, 1/2 vests on the grant date, 1/4 on the one-year anniversary, and 1/4 on the second anniversary, and the option expires on January 2, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fritz Frederick J.

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NJ 08648

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.95(1)	01/02/2026		A		5,892		01/02/2026(2)	01/02/2036	Common Stock	5,892	$0	5,892	D

Explanation of Responses:

1. Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

2. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

	/s/ Susan Eylward, Attorney-in-Fact for Frederick J. Fritz	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Imunon (IMNN) disclose for Frederick J. Fritz?

The filing shows that director Frederick J. Fritz received a stock option grant for 5,892 shares of Imunon, Inc. common stock on January 2, 2026.

What are the key terms of Frederick J. Fritz’s Imunon (IMNN) stock option grant?

The grant is a Stock Option (Right to Buy) for 5,892 shares at an exercise price of $3.95 per share, with 5,892 derivative securities beneficially owned after the transaction.

How does the Imunon (IMNN) stock option granted to Frederick J. Fritz vest?

The options vest as follows: 1/2 on the date of grant, 1/4 on the one-year anniversary of the grant date, and 1/4 on the second-year anniversary of the grant date.

When do the stock options granted to Frederick J. Fritz at Imunon (IMNN) expire?

The stock options granted to Frederick J. Fritz have an expiration date of January 2, 2036.

What price was used to set the exercise price of Frederick J. Fritz’s Imunon (IMNN) options?

A footnote states the $3.95 exercise price represents the closing price of Imunon, Inc. common stock on the grant date.

Is Frederick J. Fritz’s ownership in Imunon (IMNN) from this option grant direct or indirect?

The Form 4 indicates the 5,892 derivative securities from this option grant are held under direct ownership by Frederick J. Fritz.